Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Sprechen Sie mit dem Deal-Team
PrincipalTel Aviv, Israel
PartnerTel Aviv, Israel
Assistant to Executive BoardTel Aviv, Israel
Iofina secures new debt refinancing
Iofina Plc has refinanced its entire debt by entering into a new loan agreement with First Financial Bank, (NASDAQ: FFBC), a Cincinnati-headquartered US regional bank.Mehr erfahren
SCS Computers has been acquired by MAPS Group
The private shareholders of SCS Computers, an Italian software company specialized in the healthcare sector, have sold the company to MAPS Group.Mehr erfahren
GeneTech Inc. has been acquired by Eurofins
Noritsu Koki Co., Ltd. has sold GeneTech Inc. to Eurofins Clinical Testing Holding Lux S.à r.l.Mehr erfahren